Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs

• Published in: International journal of toxicology Vol. 31; no. 1; p. 58
• Main Authors: Yerramilli-Rao, Padmaja, Beal, M Flint, Watanabe, Dai, Kieburtz, Karl, Blieck, Elisabeth A de, Kitano, Mitsuaki, Hosoe, Kazunori, Funahashi, Iwao, Cudkowicz, Merit E
• Format: Journal Article
• Language: English
• Published: United States 01.01.2012
• Subjects: Administration, Oral; Animals; Area Under Curve; Dogs; Female; Male; Neuroprotective Agents - blood; Neuroprotective Agents - pharmacokinetics; Neuroprotective Agents - toxicity; Toxicity Tests, Acute; Toxicity Tests, Chronic; Ubiquinone - analogs & derivatives; Ubiquinone - blood; Ubiquinone - pharmacokinetics; Ubiquinone - toxicity
• ISSN: 1092-874X
• DOI: 10.1177/1091581811425256

To support phase III testing of coenzyme Q10 (CoQ₁₀) in humans, we conducted pharmacokinetic and toxicology studies in beagle dogs. Following single gavage administration of CoQ₁₀ at 600, 1200, 1800, or 2400 mg/kg per d no obvious dose response was observed in maximum concentration (C(max)) or area under the curve (AUC) versus time curve at the 3 highest dosages. In a repeated-dose study of CoQ₁₀ at 600, 1200, 1800, or 2400 mg/kg per d for 4 weeks, CoQ₁₀ reached steady state in plasma by 2 weeks at all dosages. Both C (max) and AUC increased with increasing dosage of CoQ₁₀. The highest plasma levels were recorded at 1800 mg/kg per d. In a 39-week chronic toxicity study of CoQ₁₀ at 1200 and 1800 mg/kg per d or placebo, CoQ₁₀ reached steady state in plasma by 13 weeks. Behaviors, blood chemistries, and detailed histopathology were normal. No deaths occurred. These results support the use of a 2400 mg/d dosage of CoQ₁₀ in human clinical trials.